Identification of Novel Trypanosoma cruzi Cysteine Protease Inhibitors via Ligand-Based Virtual Screening of FDA-Approved Drugs with Trypanocidal Activity
These results encourage the development of new and more potent anti-<i>Trypanosoma cruzi</i> agents using FDA-approved drugs as scaffolds.
Authors
- Ana Verónica Martínez-Vázquez (ORCID: https://orcid.org/0000-0002-6144-5439)
- C Aguirre-Alvarado
- Lenci K. Vázquez‐Jiménez (ORCID: https://orcid.org/0000-0002-9327-9658)
- Rogelio Gómez-Escobedo
- Eyra Ortíz-Pérez (ORCID: https://orcid.org/0000-0003-3800-0228)
- Veronica Alcantara-Farfán
- G Gibrán Rivera
- Alonzo González-González
- L. Rodríguez-Páez
- Benjamín Nogueda‐Torres
- Adriana Moreno-Rodriguez
- Timoteo Delgado-Maldonado
- Joaquín Cordero-Martínez
Institutions
- Secretaría de Ciencia Tecnología e Innovación (MX)
- Instituto Politécnico Nacional (MX)
- Benito Juárez Autonomous University of Oaxaca (MX)
Publication Details
- Journal
- Diseases
- Published
- 2026-02-19
- DOI
- https://doi.org/10.3390/diseases14020079
- Primary Topic
- Trypanosoma species research and implications
- Type
- article
- Field-Weighted Citation Impact
- 0.00